The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint
Open accessAbstract
Antiresorptive treatments for postmenopausal osteoporosis have been studied extensively, but due to the volume of published data and lack of head-to-head trials, it is difficult to evaluate and compare their fracture reduction efficacy. The objective of this review is to summarize the results from clinical trials that have fracture as an endpoint and to discuss the factors in study design and populations that can affect the interpretation of the results. Although there are numerous observational studies suggesting that estrogen and hormone replacement therapies may reduce the risk of vertebral and nonvertebral fractures, there is no large, prospective, randomized, placebo-controlled, double-blind clinical trial demonstrating fracture efficacy. The effects of raloxifene, alendronate, risedronate, and salmon calcitonin on increasing bone mineral density (BMD) and decreasing fracture risk have been shown in randomized, placebo-controlled, double-blind clinical trials of postmenopausal women with osteoporosis. Although the increases in lumbar spine BMD vary greatly in these trials, the decrease in relative risk of vertebral fractures is similar among therapies. However, nonvertebral fracture efficacy has not been consistently demonstrated. Combined administration of two antiresorptive therapies results in greater BMD increases, but the effects on fracture risk are unknown. Direct comparisons of clinical trial results should be considered carefully, given the differences in study design and populations. Differences in study design that may influence the efficacy of fracture risk reduction include calcium and vitamin D supplementation, primary fracture endpoints, definition of vertebral deformity or fracture, discontinuation rates, and statistical power. Factors in the study population that may influence fracture efficacy include the age of the population and the proportion of subjects with prevalent fractures. The use of surrogate endpoints such as BMD to predict fracture risk should be approached with caution, as the relationship between BMD changes and fracture risk reduction with antiresorptive therapies is uncertain. Consideration of these results from clinical trials can contribute to clinical judgment in selecting the best treatment option for postmenopausal osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Updated Data on Proximal Femur Bone Mineral Levels of US Adults
Looker, A. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., Johnston Jr, C. C., & Lindsay, R. (1998) · Osteoporosis International · doi:10.1007/s001980050093 · Cited by 1,121
Cited by
Marx, R. E., Cillo, J. E., & Ulloa, J. J. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2007.08.003 · Cited by 720
Becker, K. L., Nylén, E. S., White, J. C., Müller, B., & Snider, R. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021444 · Cited by 578
Khosla, S. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.01.054 · Cited by 564
Delmas, P. D., Genant, H. K., Crans, G. G., Stock, J. L., Wong, M., Siris, E., & Adachi, J. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00241-2 · Cited by 545
Self-citationRosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Metadata
- Authors
- Marcus, R., Wong, M., Heath, H., & Stock, J. L.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2002-02-01
- Volume
- 23
- Issue
- 1
- Pages
- 16-37
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W1966391931
- Cited by
- 164
- References
- 16
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint. https://app.cochat.ai/papers/10.1210/edrv.23.1.0453
- The paper
- Marcus, R., Wong, M., Heath, H., & Stock, J. L. (2002). Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint. Endocrine Reviews. https://doi.org/10.1210/edrv.23.1.0453
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.